141 related articles for article (PubMed ID: 24528941)
1. FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma.
Choi SH; Chang JS; Jeong YH; Lee Y; Yun M; Seong J
Liver Int; 2014 Aug; 34(7):1118-25. PubMed ID: 24528941
[TBL] [Abstract][Full Text] [Related]
2. FDG PET uptake as a predictor of pain response in palliative radiation therapy in patients with bone metastasis.
Adli M; Kuzhan A; Alkis H; Andic F; Yilmaz M
Radiology; 2013 Dec; 269(3):850-6. PubMed ID: 23985277
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy.
Kim JW; Seong J; Yun M; Lee IJ; Yoon HI; Cho HJ; Han KH
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1172-8. PubMed ID: 21570203
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.
Kim BK; Kang WJ; Kim JK; Seong J; Park JY; Kim DY; Ahn SH; Lee DY; Lee KH; Lee JD; Han KH
Cancer; 2011 Oct; 117(20):4779-87. PubMed ID: 21469082
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
7. Fluorodeoxyglucose Uptake on Positron Emission Tomography Is a Useful Predictor of Long-Term Pain Control After Palliative Radiation Therapy in Patients With Painful Bone Metastases: Results of a Single-Institute Prospective Study.
Tahara T; Fujii S; Ogawa T; Michimoto K; Fukunaga T; Tanino T; Uchida N; Matsuki T; Sakamoto H
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):322-8. PubMed ID: 26853340
[TBL] [Abstract][Full Text] [Related]
8. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
9. [Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma].
Kong YH; Han CJ; Lee SD; Sohn WS; Kim MJ; Ki SS; Kim J; Jeong SH; Kim YC; Lee JO; Cheon GJ; Choi CW; Lim SM
Korean J Hepatol; 2004 Dec; 10(4):279-87. PubMed ID: 15613803
[TBL] [Abstract][Full Text] [Related]
10. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
11. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
[TBL] [Abstract][Full Text] [Related]
12. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma.
Ho CL; Chen S; Cheng TK; Leung YL
Radiology; 2011 Feb; 258(2):515-23. PubMed ID: 21062922
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
14. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.
Song HJ; Cheng JY; Hu SL; Zhang GY; Fu Y; Zhang YJ
Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and
Rhee WJ; Hwang SH; Byun HK; Yun M; Han KH; Seong J
Liver Int; 2017 Apr; 37(4):592-599. PubMed ID: 27804192
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
17. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
19. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
[TBL] [Abstract][Full Text] [Related]
20. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
